{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"1.84","value":"0.9"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"3.6","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Duration of response is defined as the time between each patient's best tumor response and progression (or date of last disease assessment for patients who die without progression or are lost to follow-up). Complete Response (CR): All of the following must be true: a. Disappearance of all target lesions. b. Each target lymph node must have reduction in short axis to \\< 1.0 cm. Partial Response (PR): At least a 30% decrease in PBSD taking as reference the BSD.","dispersionType":"Full Range","groups":[{"description":"Protocol therapy will consist of 30 mg MLN0128 (TAK-228) administered weekly over a 4-week cycle.","id":"OG000","title":"Phase II - Analysis Group 2 MLN0128"},{"description":"Patients receive 400mg Pazopanib orally once daily over a 4-week cycle and titrated to tolerance (maximum 800mg) by the treating physician in the first intervention period/initial treatment period.","id":"OG001","title":"Phase II - Analysis Group 2 Pazopanib"}],"paramType":"MEDIAN","populationDescription":"Phase II Analysis Group 2 - Initial Treatment Period; Only patients that had a complete response or partial response are included in this analysis.","reportingStatus":"POSTED","timeFrame":"Time between each patient's best tumor response and progression(or date of last disease assessment for patients who die without progression or are lost to follow-up), assessed up to 2 years","title":"Duration of Response (Phase II Analysis Group 2 - Initial Treatment Period)","type":"SECONDARY","unitOfMeasure":"months"}